Mechanisms that alter protein phosphatase 2A (PP2A)-dependent lung tumour suppression via the I2PP2A/SET oncoprotein are unknown. We show here that the tumour suppressor ceramide binds I2PP2A/SET selectively in the nucleus and including its K209 and Y122 residues as determined by molecular modelling/simulations and site-directed mutagenesis. Because I2PP2A/SET was found overexpressed, whereas ceramide was downregulated in lung tumours, a sphingolipid analogue drug, FTY720, was identified to mimick ceramide for binding and targeting I2PP2A/SET, leading to PP2A reactivation, lung cancer cell death, and tumour suppression in vivo. Accordingly, while molecular targeting of I2PP2A/SET by stable knockdown prevented further tumour suppression by FTY720, reconstitution of WT-I2PP2A/SET expression restored this process. Mechanistically, targeting I2PP2A/SET by FTY720 mediated PP2A/RIPK1-dependent programmed necrosis (necroptosis), but not by apoptosis. The RIPK1 inhibitor necrostatin and knockdown or genetic loss of RIPK1 prevented growth inhibition by FTY720. Expression of WT- or death-domain-deleted (DDD)-RIPK1, but not the kinase-domain-deleted (KDD)-RIPK1, restored FTY720-mediated necroptosis in RIPK1−/− MEFs. Thus, these data suggest that targeting I2PP2A/SET by FTY720 suppresses lung tumour growth, at least in part, via PP2A activation and necroptosis mediated by the kinase domain of RIPK1.
PP2A is a master tumour suppressor enzyme involved in the regulation of key oncoproteins, such as c-Myc and Bcr-Abl in various cancer types including lung cancers and CML, respectively. In addition to inactivation mutations of PP2A, there are biological inhibitors, such as inhibitor 2 of PP2A (I2PP2A/SET oncoprotein), which directly binds and inhibits PP2A function. However, mechanisms involved in the regulation of PP2A-I2PP2A/SET interaction for controlling PP2A-dependent tumour suppression in cancer cells have been enigmatic.
In this study, molecular modelling and simulations coupled with site-directed mutagenesis indicated that the endogenously generated tumour suppressor C18-ceramide binds I2PP2A/SET through the hydrophobic-binding pocket, which is localized within the two anti-parallel beta sheet stabilized loops and an extended alpha helix, including the K209/Y122 residues. In addition, data revealed that I2PP2A/SET is highly expressed while C18-ceramide is downregulated in the majority of primary human lung tumours compared to their adjacent normal lung tissues, suggesting that I2PP2A/SET might present a key target to reactivate PP2A tumour suppressor signalling. Accordingly, we explored the therapeutic potential of targeting I2PP2A/SET using a sphingosine derivative drug, FTY720 (Fingolimod), which mimicked ceramide for binding I2PP2A/SET, leading to PP2A reactivation, and lung cancer cell death via, at least in part, RIPK1-dependent programmed necrosis, independently of its immune suppression function.
The data presented here provide structural and molecular details of ceramide/FTY720-I2PP2A/SET binding via lipid–protein interaction, which in turn leads to reactivation of tumour suppressor PP2A and induction of necroptosis, resulting in lung cancer cell death. Overall, these results suggest a novel mechanism-based strategy for the inhibition of lung tumour growth via targeting I2PP2A/SET oncoprotein by a sphingosine analogue drug FTY720, indicating that future development of novel small molecule inhibitors of I2PP2A/SET might be efficacious for the treatment of lung cancers.
Protein phosphatase 2A (PP2A) is a tumour suppressor enzyme (Eichhorn et al, 2009; Westermarck & Hahn, 2008) involved in the regulation of oncoproteins, such as c-Myc (Yeh et al, 2004) and Bcr-Abl (Salas et al, 2011), in various cancers including lung cancers and CML, respectively. In addition to inactivating mutations of PP2A (Westermarck & Hahn, 2008), there are biological inhibitors, such as inhibitor 2 of PP2A (I2PP2A/SET oncoprotein), which directly binds and modulates PP2A function (Li et al, 1996). However, mechanisms involved in the regulation of PP2A-I2PP2A/SET interaction for controlling PP2A-dependent tumour suppression in human cancer cells have been largely unknown.
Ceramide activates PP2A (Chalfant et al, 1999; Ogretmen and Hannun, 2004) in part via directly binding I2PP2A/SET, which relieves PP2A from the inhibitor, thus increasing PP2A activity (Mukhopadhyay et al, 2009). However, whether endogenous ceramides, which are generated de novo by ceramide synthases 1–6 (CerS1–6) (Pewzner-Jung et al, 2006), also bind I2PP2A/SET remain unknown.
FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; Fingolimod, Novartis), a synthetic sphingosine analogue of myriocin, regulates sphingosine-1-phosphate receptor signalling and suppresses autoimmunity upon its phosphorylation by sphingosine kinase-2 (SK-2) (Billich et al, 2003; Paugh et al, 2003). FTY720 has been approved by the FDA for treatment of patients with refractory multiple sclerosis (Cohen et al, 2010) and has been shown to exert anti-cancer functions against CML (Neviani et al, 2007) and GISTs via activation of PP2A (Roberts et al, 2010) by an unknown mechanism.
Although induction of apoptosis via Bax/Bak-dependent caspase activation is important for anti-cancer therapeutics, necroptosis via activation of RIPK1 (Thon et al, 2005) might also play a role in this process (Bonapace et al, 2010; Degterev et al, 2008). However, involvement of RIPK1-induced necroptosis in lung tumour suppression via I2PP2A/SET targeting by FTY720 has not been reported previously. Here, using molecular modelling/simulations and site-directed mutagenesis, we determined the structural details of endogenous ceramide and I2PP2A/SET binding. Ceramide was found altered in lung tumours, whereas I2PP2A/SET was highly expressed in the majority of these tissues. We then examined whether tumour suppressive ceramide signalling can be restored by the sphingosine analogue drug FTY720. We discovered that FTY720 directly binds I2PP2A/SET, leading to PP2A activation and cell death. We also defined the mechanism by which FTY720 mediates cell death via induction of PP2A/RIPK1-dependent necroptosis, leading to lung tumour suppression.
Structural modelling of I2PP2A/SET-ceramide binding
To uncover the structural details of I2PP2A/SET-ceramide binding, molecular modelling/simulations were performed using the crystal structure of I2PP2A/SET (Muto et al, 2007) and C18-ceramide as a probe (Fig 1A). Our previous study showed that a single mutation with K209D conversion significantly inhibited the binding of I2PP2A/SET to ceramide both in vitro and in A549 cells (Mukhopadhyay et al, 2009). Accordingly, one of the prominent docking sites of I2PP2A/SET for ceramide binding included the K209 residue (Fig 1A and B, and Supporting Information Fig S1), which interacts with the primary hydroxyl group of ceramide possibly via charge attraction (Fig 1B, and Supporting Information Fig S1). The model also suggested that the K209 directly interacts with the Y122 residue via a hydrophobic–ionic (cation/π-arene) interaction (Fig 1B), possibly playing a role as a gate for regulating the access of ceramide to the hydrophobic pocket.
Binding preferences of I2PP2A/SET with endogenous ceramides in A549 cells
To determine the possible involvement of K209 and Y122 residues in ceramide binding, we generated K209D and Y122C mutants of I2PP2A/SET. The K209D point mutation introduces negatively charged aspartic acid in place of lysine, which is predicted to cause electron repulsion with the 1-OH of ceramide, thus decreasing ceramide binding. In addition, the interaction between K209 and Y122 might form a cation/π-arene interaction. Thus, the conversion of Y122 to C122 should eliminate the interaction and open the gate for the hydrophobic pocket, which should increase ceramide binding. To examine the preference of Y122C or K209D mutations with endogenous ceramide binding, WT-, K209D- and Y122C-I2PP2A/SET-GFP proteins were expressed in A549 cells and accumulated in the nucleus like endogenous I2PP2A (Mukhopadhyay et al, 2009) (Fig 1C). Using anti-GFP columns, I2PP2A/SET-GFP was pulled down and protein-bound ceramides were measured after lipid extraction from the pulled down protein extracts followed by LC/MS/MS (Fig 1D and E; Supporting Information Fig S2). The data revealed that WT-I2PP2A/SET preferentially binds C18-ceramide (about 30% of total C18-ceramide) over C14–C16-ceramides in A549 cells compared to vector-transfected controls (Fig 1D and E, and Supporting Information Fig S2). In addition, WT-I2PP2A/SET also bound to C20- (1.9-fold), C22- (2.6-fold), C24- (2.1-fold) and C26-ceramide (2.5-fold) compared to the K209D-I2PP2A/SET in A549 cells (Supporting Information Fig S2). Thus, these data suggest that I2PP2A/SET preferentially binds C18-ceramide and, to a lesser extent, C20–C26-ceramides. As the model suggested, the Y122C-I2PP2A/SET increased binding to C18-, C20-, C22- and C26-ceramide around 2.5-, 4.2-, 4.6-, 3.2- and 2.4-fold, respectively, compared to vector-transfected controls (Supporting Information Fig S2). In contrast, the K209D mutation of I2PP2A/SET decreased binding to C18–C26 ceramides, except for C14-ceramide (Supporting Information Fig S2). Thus, these data suggest that the K209D conversion significantly decreases the binding of I2PP2A/SET to C18–C26-ceramides, while the Y122C mutation enhances ceramide binding, supporting the cation/π-arene gating system of the I2PP2A/SET–ceramide complex.
Effects of sub-cellular localization of I2PP2A/SET on ceramide binding
To examine whether sub-cellular localization of I2PP2A/SET plays a role in its binding selectivity to endogenously generated ceramides, we generated a mutant of I2PP2A/SET for ER localization/retention (Senkal et al, 2011), where de novo ceramide synthesis occurs. We confirmed the ER localization of this mutant (ER-I2PP2A/SET-GFP) versus WT-I2PP2A/SET-GFP, K209D-I2PP2A/SET-GFP and Y122C-I2PP2A/SET-GFP using confocal microscopy/immunofluorescence by co-localization of GFP with the ER protein calnexin (Fig 1C). Wt- and mutant-I2PP2A/SET-GFP expression was confirmed by Western blotting (Supporting Information Fig S3). The ER-I2PP2A/SET-GFP was preferentially expressed in the ER, whereas WT-, K209D- and Y122C-I2PP2A/SET-GFP were localized mainly in the nucleus of A549 cells (Fig 1C). We then examined binding of ER-I2PP2A/SET-GFP to endogenous ceramides in A549 cells after pull-down studies using anti-GFP columns followed by lipid extraction and LC/MS/MS (Fig 1D and E, and Supporting Information Fig S2). Interestingly, retention of I2PP2A/SET in the ER shifted its binding preference towards C16-ceramide over C18-ceramide compared to WT-I2PP2A/SET in situ (Fig 1D and E), which was independent of their relative concentrations in the ER versus nucleus; C16-ceramide was higher than C18-ceramide in both cytoplasm and nucleus (see Supporting Information Fig S4A). Moreover, targeting mutation of the ER-I2PP2A/SET-GFP had no inhibitory effect on its binding activity to ceramide compared to WT-I2PP2A in vitro (Supporting Information Fig S4B). Thus, these data suggest that ceramide-binding selectivity is mainly regulated by the sub-cellular localization of I2PP2A/SET and availability of ceramides, rather than their fatty acid chain lengths, in ER versus nuclear membranes.
I2PP2A/SET is a novel target for lung cancer
Binding of I2PP2A/SET to ceramide in lung cancer cells might have clinical and biological significance. To define the clinical relevance of I2PP2A/SET-C18-ceramide in cancer pathogenesis, we measured I2PP2A/SET and C18-ceramide in tumour versus pathologically non-cancerous adjacent lung tissues obtained from 10 patients with NSCLC using Western blotting and immunohistochemistry (IHC; Fig 2A and B). Data showed that I2PP2A/SET is overexpressed in 70% (7/10, n = 10) of these tumours (Fig 2A), whereas C18-ceramide and CerS1 mRNA levels are decreased (∼50%) in the majority of tumours (8/10, n = 10) compared to non-cancerous lung tissues (Fig 2C and D, respectively). Importantly, at least 4 of 10 patients exhibited overexpression of I2PP2A/SET in combination with down-regulation of C18-ceramide in their lung tumours, suggesting that tumour suppressive ceramide/PP2A signalling is altered in these tumours (Fig 2C and D). However, C16-ceramide was significantly higher (∼1.8-fold, p < 0.01, n = 10) in tumour compared to non-cancerous lung tissues, and there were no significant changes in the levels of other ceramide species (Supporting Information Fig S5).
The significance of I2PP2A/SET in lung tumours was further explored by IHC using a tumour micro-array (TMA) containing lung adenocarcinoma (n = 48), adjacent lung (n = 48) and normal lung tissues (n = 4). I2PP2A/SET expression was significantly higher in 47 of 48 (p < 0.001) lung tumours when compared to adjacent and normal lung tissues (Fig 2E, left and right panels). These data suggest that PP2A might be inhibited in lung tumours, because its biological inhibitor I2PP2A/SET is highly expressed, whereas PP2A activator C18-ceramide (Mukhopadhyay et al, 2009) is lower in these tumour tissues compared to controls. In fact, an inactive p-PP2A (Y307) was elevated in the majority of lung tumours compared to paired non-cancerous lung tissues (Supporting Information Fig S6). Overall, these data suggest that targeting I2PP2A/SET might be a novel therapeutic strategy for the treatment of NSCLC to reactivate PP2A tumour suppressor signalling.
FTY720 directly binds I2PP2A/SET
Targeting I2PP2A/SET exogenously with a sphingolipid analogue drug that mimics ceramide and/or sphingosine could potentially bind I2PP2A/SET and reactivate PP2A tumour suppressor signalling (Mukhopadhyay et al, 2009). Since exogenous (Mukhopadhyay et al, 2009) and endogenous sphingosine (Fig 3A) bind wt-I2PP2A/SET, but not K209D-I2PP2A/SET, in A549 cells (Fig 3A), we examined whether sphingosine analogue FTY720, which was shown to inhibit tumour growth (Liu et al, 2010; Neviani et al, 2007; Pchejetski et al, 2010; Wallington-Beddoe et al, 2011), binds/targets I2PP2A/SET. We performed molecular docking studies based on I2PP2A/SET–ceramide modelling (Fig 1A and B), which predicted that one of the primary hydroxyl groups of FTY720 might bind to the K209 residue of I2PP2A/SET (Fig 3B and Supporting Information Fig S7). Biotin-labelled FTY720 (B-FTY720) was incubated with purified I2PP2A/SET, drug-bound proteins were then separated through an avidin column, and B-FTY720-bound I2PP2A/SET was detected by Western blotting using anti-I2PP2A/SET antibody. Remarkably, FTY720 (5–10 µM) also bound directly to purified I2PP2A/SET in vitro or endogenously expressed I2PP2A/SET in A549 cells (Fig 3C).
Then, to explore the role of K209 and Y122 residues in the interaction between FTY720 and I2PP2A/SET, the K209D-, Y122C- or WT-I2PP2A/SET-GFP were expressed in A549 cells, and their binding to B-FTY720 was examined as compared to biotin-only-treated controls. The K209D mutation decreased I2PP2A/SET-FTY720 binding (∼20%), whereas the Y122C conversion increased its FTY720 binding (∼45%) compared to WT-I2PP2A/SET, which was considered as 100%, compared to biotin-only-treated controls (Fig 3D). Collectively, these data suggest that FTY720 directly binds I2PP2A/SET both in vitro and in situ, and that K209/Y122 residues are involved in FTY720-I2PP2A/SET binding, mimicking ceramide as predicted by molecular modelling.
Moreover, binding of FTY720 to purified recombinant human I2PP2A/SET, containing a histidine (His) tag, was also confirmed by surface plasmon resonance (SPR) (Stahelin and Cho, 2001). To quantitatively determine the binding affinity of I2PP2A/SET for liposomes harbouring ceramide, FTY720 or FTY720P, we performed SPR, which directly measures lipid–protein interactions. In these experiments, an active surface was coated with POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)/POPE (1-palmitoyl-2-oleoyl-snglycero-3-phospho-ethanolamine)-ceramide, FTY720 or P-FTY720 (75:20:5). A control surface was then coated with POPC/POPE (80:20). Recombinant purified I2PP2A/SET or control p47phox-PX, a phosphoinositide binding domain of p47, which does not bind ceramide, were injected at 1 µM across the active and control surfaces to determine the relative binding for each of the lipids. As shown in Fig 3E, I2PP2A/SET displayed substantial binding to liposomes containing ceramide or FTY720, but binding to P-FTY720 was not detectable. Relative kinetic binding constants ± the standard deviation for 3 replicates are shown in Fig 3F. I2PP2A/SET bound with similar affinity (Kd = ∼11 nM) to vesicles containing C18-ceramide or FTY720 (Table 1), whereas Kd for P-FTY720 was below the detection limit (Table 1). Moreover, a control lipid binding domain p47phox-PX, which has previously been shown to bind to PI(3,4)P2 and phosphatidic acid (Karathanassis et al, 2002), did not display detectable binding on any of the surfaces (Table 1). Overall, these data support the binding preference of I2PP2A/SET for C18-ceramide and FTY720 over P-FTY720 in vitro.
Table 1. Binding of purified human I2PP2A/SET to C18-ceramide, FTY720 and P-FTY720 in vitro, measured using SPR
Protein Kd (nM)
Kd values determined with SPR. All data was collected at 1 µM I2PP2A in 20 mM HEPES, pH 7.4 buffer containing 160 mM KCl.
Liposomes contained POPC:POPE:x at (75:20:5) ratio while control liposomes contained POPC:POPE at a (80:20) ratio.
N.D. refers to not detectable on the indicated surface.
Treatment with FTY720 suppresses A549-xenograft-derived tumour growth
Because FTY720 directly bound I2PP2A/SET, we explored its ability to inhibit tumour growth via activation of PP2A tumour suppressor signalling. The therapeutic potential of FTY720 against A549-xenografts generated in the flanks of SCID mice was determined after oral administration of FTY720 (3 mg/kg/day for 15 days, n = 12) (LaMontagne et al, 2006). FTY720 significantly (p < 0.05, n = 12) inhibited the growth of A549-xenograft-derived tumours compared to controls (Fig 4A). To examine whether FTY720-mediated tumour suppression was linked to PP2A activation, we examined P-PP2A (inactive) and PP2A (total) in tumours obtained from control versus FTY720-treated animals. The data showed that FTY720 treatment decreased inactive P-PP2A (Y307) without affecting total PP2A compared to controls (Fig 4B, upper and middle right/left panels, respectively), suggesting PP2A activation. Because activation of PP2A results in c-Myc degradation (Mukhopadhyay et al, 2009), leading to inhibition of human telomerase reverse transcriptase (hTERT) transcription, we also confirmed FTY720-mediated PP2A activation by measuring c-Myc and hTERT in these tumour tissues. Activation of PP2A by FTY720 was consistent with decreased c-Myc (as detected using IHC or Western blotting) and hTERT mRNA (measured by Q-PCR) in these tumours compared to controls (Fig 4B, lower panel, or Supporting Information Fig S8A and B). In addition, examination of the tumours by transmission electron microscopy (TEM) revealed that ∼40% of tumours (n = 20) obtained from mice treated with oral FTY720 had damaged/swollen mitochondria consistent with cellular damage leading to inhibition of tumour growth (Fig 4C).
To confirm that the oral drug treatments resulted in effective FTY720 delivery, we measured FTY720 and P-FTY720 in tumour tissues and serum samples obtained from FTY720-treated mice compared to controls using LC/MS/MS. The data showed that FTY720 accumulated in the A549-xenograft-derived tumours (Fig 4D) reaching 0.2 pmol/nmol Pi, whereas P-FTY720 was much lower in tumours (0.05 pmol/nmol Pi). However, accumulation of P-FTY720 was higher in the serum of animals than FTY720, with ∼400 pmol/ml versus ∼100 pmol/ml, respectively (Fig 4D). Thus, these data suggest that FTY720-mediated tumour suppression is associated to PP2A activation in vivo, and whereas FTY720 accumulates preferentially in tumour tissues, P-FTY720 mainly accumulates in the serum.
Because FTY720 was shown to alter ceramide metabolism (Berdyshev et al, 2009; Lahiri et al, 2009), we explored whether treatment with FTY720 resulted in changes in ceramide accumulation in A549-xenograft-derived tumours and serum of SCID mice. Interestingly, we found no significant changes in total ceramide levels in the tumour or serum of mice treated with oral doses of FTY720 (Supporting Information Fig S8C).
Phosphorylation of FTY720 might be dispensible for its I2PP2A/SET binding or tumour suppressor activity
Phosphorylation of FTY720 is catalysed by nuclear SK-2, and it is required for its immune-suppressor and anti-MS activities (Billich et al, 2003; Paugh et al, 2003). However, whether P-FTY720 generation plays a role in I2PP2A/SET binding or tumour suppression is unknown. Therefore, we first examined whether P-FTY720 is necessary for its I2PP2A/SET binding in A549 cells. To achieve this, purified I2PP2A/SET was incubated with B-FTY720 in the absence/presence of unlabeled C18-Pyr-Cer, FTY720 or P-FTY720 as competitors. Incubation with unlabeled C18-ceramide or FTY720, but not P-FTY720, competed significantly with B-FTY720-I2PP2A/SET binding (Fig 5A). These data suggest that P-FTY720 is not as efficient as FTY720 to bind I2PP2A/SET, supporting our molecular modelling (Fig 3B) and in vitro SPR studies (Fig 3E and F), which suggested that presence of a primary hydroxyl group in the FTY720 structure is important for I2PP2A/SET binding and that I2PP2A/SET has a lower affinity to P-FTY720 compared to C18-ceramide and FTY720, respectively.
Because P-FTY720 did not compete with B-FTY720/I2PP2A/SET binding, we explored if the phosphorylation of FTY720 by SK-2 is necessary for its tumour suppressor roles via activation of PP2A. To examine if PP2A is activated by P-FTY720, which leads to c-Myc degradation (Mukhopadhyay et al, 2009; Yeh et al, 2004), A549 cells were treated with FTY720 or P-FTY720, and c-Myc was measured by Western blotting. FTY720, but not P-FTY720, decreased c-Myc levels compared to controls (Fig 5B). Additionally, we investigated whether genetic loss of SK2, in SK2−/− MEFs, modulated FTY720-mediated c-Myc expression, a known endogenous target for PP2A, or cell survival compared to controls. MEFs obtained from WT, SK-1−/−, and SK-2−/− mice were ectopically transfected with cMyc-V5 and treated with FTY720, which resulted in reduced c-Myc expression in WT, SK-1−/− and SK-2−/− MEFs by 80, 70, and 55%, respectively, compared to their controls (Fig 5C). Additionally, the IC50 values of FTY720 against WT, SK1−/− and SK2−/− MEF's were comparable (∼10 µM; Supporting Information Fig S9). Accordingly, shRNA-mediated stable knockdown of SK-2 (∼75% compared to controls as detected by q-PCR, Supporting Information Fig S9B), had no preventive effect and further increased FTY720-induced cell death compared to Scr-shRNA-transfected A549 cells (Supporting Information Fig S9C). These data suggest that phosphorylation of FTY720 by SK-2 might be dispensible for the regulation of the PP2A/c-Myc axis and growth inhibitory roles of FTY720 in A549 cells.
To examine if P-FTY720 is involved in targeting I2PP2A/SET leading to tumour growth inhibition in vivo, we implanted Lewis lung adenocarcinoma cell (LLC)-derived allografts in the flanks of SK-2−/− compared to WT mice and treated with oral doses of 10 mg/kg FTY720. The genetic loss of SK-2 significantly (p < 0.05) reduced the growth of LLC-derived allografts in the flanks of SK-2−/− compared to WT mice and, more importantly, treatment with FTY720 (10 mg/kg/day, via oral delivery) was efficacious against LLC-allografts grown in WT and SK-2−/− mice, inhibiting tumour growth by ∼60 and 47%, respectively, compared to their controls (Fig 5D and E). Interestingly, the loss of SK-2 almost completely abrogated the accumulation of P-FTY720 in the serum of SK-2−/− mice (Fig 5F), whereas FTY720 accumulation was comparable in the tumours grown in WT and SK-2−/− mice (Fig 5G). P-FTY720 was lower than FTY720 in the tumours grown in WT and SK-2−/− animals (Fig 5G). Thus, these data support that SK-2 is important for the generation and accumulation of P-FTY720 in the serum and that SK-2-dependent P-FTY720 may not be required for mechanisms of tumour suppression that are dependent on I2PP2A/SET-targeting. It should be noted that loss of SK-2 had slight protective effects against c-Myc degradation and tumour suppression (∼20–30%) in SK-2−/− MEFs or SK-2−/− k/o mice, respectively, compared to controls (Fig 5C–E). These data indicate that there might be a role for P-FTY720 in the regulation of tumour growth, possibly via I2PP2A/SET/PP2A-independent mechanisms. Nevertheless, our data indicate that immune suppressor and lung tumour suppressor functions of P-FTY720 and FTY720 are distinct, consistent with their preferential accumulation in the serum versus lung tumour tissues, respectively.
Targeting I2PP2A/SET by FTY720 leads to growth inhibition via PP2A activation
To examine whether binding/targeting of I2PP2A/SET by FTY720 inhibits lung tumour growth via PP2A activation, we measured PP2A activity in response to shRNA-mediated I2PP2A knockdown (∼90%) in A549 cells (Fig 6A). Then, effects of WT-I2PP2A/SET reconstitution (∼60%) in A549/sh-I2PP2A/SET cells on PP2A activity in response to FTY720 was also measured compared to controls (Fig 6A). Interestingly, whereas FTY720 enhanced PP2A activity compared to vehicle-treated controls, knockdown of I2PP2A/SET also significantly enhanced PP2A activity, but prevented its further activation by FTY720 (Fig 6B). In contrast, when WT-I2PP2A/SET was restored in A549/sh-I2PP2A/SET cells, the PP2A activity was increased in response to FTY720 (Fig 6B). Thus, these data suggest that FTY720 activates PP2A via targeting I2PP2A/SET.
To examine whether I2PP2A/SET-FTY720 binding inhibits growth in lung cancer cells via PP2A activation, we pre-treated cells with okadaic acid (OA, 10 nm), a PP2A inhibitor, and detected that inhibition of PP2A prevented FTY720-mediated growth suppression (Fig 6C). Moreover, siRNA-mediated knockdown of PP2A [∼70% compared to scrambled (SCR) siRNA-transfected cells; Fig 6D, left panel] inhibited PP2A activity around 70% (Fig 6D, right panel) and attenuated FTY720-mediated cell death measured by LDH release to the media (Fig. 6E). In reciprocal experiments, overexpression of PP2A-HA, as confirmed by Western blotting (Supporting Information Fig S10A), increased FTY720-mediated cell death ∼40% compared to controls (Fig 6F). In these studies, it was noted that overexpression of PP2Ac itself had no significant effect on cell viability compared to vector-transfected controls (Fig 6F). PP2A forms over 150 interprotein and 570 intraprotein complexes (Herzog et al, 2012). Therefore, it is difficult to interpret the effects of overexpression of the catalytic subunit of PP2A itself on cell viability, because it is unknown, which specific PP2A interprotein or intraprotein complexes are involved in its tumour suppressor function after being released from I2PP2A/SET in response to FTY720. These data suggest then that FTY720 might not only relieve PP2Ac from the inhibitor, but it might also induce its anti-tumour activity via mediating specific interprotein or intraprotein complexes of PP2A (Zhang et al, 2009). This, however, needs to be further evaluated.
Targeting of I2PP2A/SET is important for tumour suppressor effects of FTY720
To validate I2PP2A/SET as a target of FTY720 for its tumour suppressor roles, we determined the effects of FTY720 on cell death and/or tumour suppression in response to shRNA-mediated knockdown of I2PP2A and its reconstitution in A549/sh-I2PP2A/SET versus A549/sh-I2PP2A/SET-WT-I2PP2A/SET cells in situ and in vivo. Treatment with FTY720 or knockdown of I2PP2A/SET alone significantly induced cell death compared to their respective controls (Fig 7A). Importantly, knockdown of I2PP2A/SET prevented FTY720-induced cell death (Fig 7A). Reconstitution of WT-I2PP2A/SET expression in A549/sh-I2PP2A/SET cells restored FTY720-mediated cell death (Fig 7A). These data were consistent with the effects of I2PP2A/SET knockdown and expression of WT-I2PP2A/SET on PP2A activation in the absence/presence of FTY720 in these cells (Fig 6B). Expression of Y122C-I2PP2A/SET-GFP and ER-I2PP2A/SET-GFP restored FTY720-mediated cell death when endogenous I2PP2A/SET was down-regulated compared to controls in A549/sh-I2PP2A/SET cells (Fig 7B). However, expression of K209D-I2PP2A/SET had no significant effect on cell death in response to FTY720 in A549/sh-I2PP2A/SET cells (Fig 7B). I2PP2A/SET-GFP expression in A549/sh-I2PP2A/SET cells was confirmed by Western blotting (Supporting Information Fig S10B).
To confirm that tumour suppressor roles of FTY720 requires I2PP2A/SET targeting in vivo, we generated xenografts in SCID mice using A549/shcontrol, A549/sh-I2PP2A/SET and A549/sh-I2PP2A/SET cells that express wt-I2PP2A/SET and assessed their growth with/without oral FTY720 treatment (3 mg/kg/day) compared to vehicle-treated controls. FTY720 inhibited the growth of A549/control-derived xenografts ∼80% compared to vehicle-treated controls (Fig 7C). Knockdown of I2PP2A/SET alone inhibited tumour growth ∼85%, however, FTY720 had no additional effects on tumour suppression in response to I2PP2A/SET knockdown. Interestingly, reconstitution of WT-I2PP2A/SET expression in A549/sh-I2PP2A/SET cells increased growth of tumours ∼50% compared to controls (Fig 7C). Expression of WT-I2PP2A/SET in A549/sh-I2PP2A/SET cells restored tumour suppressor effects of FTY720 (Fig 7C and D). Overall, these data suggest that FTY720-I2PP2A/SET binding and targeting plays a critical role, at least in part, in FTY720-mediated cell death and tumour suppression.
Because our data suggest that FTY720 mediates cell death, which can be measured by elevation of LDH released in the growth media, we next examined whether elevation of LDH in A549-xenograft-derived tumours treated with FTY720 can also be detected in the serum of mice. Total LDH released in the serum of animals containing tumours derived from A549/sh-control, A549/sh-I2PP2A/SET and A549/sh-I2PP2A/SET/WT-I2PP2A/SET cells in the absence/presence of FTY720 was measured. The data show that FTY720 or shRNA-mediated knockdown of I2PP2A/SET, both of which decreased tumour growth, increased serum LDH in mice (Fig 7E). However, FTY720 treatment had no additional effect on serum LDH in tumours expressing shRNA against I2PP2A/SET (Fig 7E), consistent with the lack of enhanced tumour growth inhibition by FTY720. Remarkably, reconstitution of WT-I2PP2A/SET in A549/sh-I2PP2A/SET enhanced serum LDH in response to FTY720, consistent with its role in restoring FTY720-mediated tumour suppression in vivo. Thus, these data suggest that tumour suppression in response to targeting I2PP2A/SET by FTY720 can be detected by the elevation of serum LDH in vivo.
FTY720 induces lung cancer cell death via RIPK1-mediated necroptosis
To delineate the downstream mechanism by which targeting I2PP2A/SET by FTY720 results in cell death [as confirmed by increased Annexin V/7-aminoactinomycin D (7-AAD) positive A549 populations compared to controls using flow cytometry; Supporting Information Fig S11A], we examined the effects of FTY720 on apoptotis- or autophagy-dependent cell death using MEFs obtained from caspase3/7−/− DKO, Bax/Bak−/− DKO or ATG5−/− KO mice. The data showed that genetic loss of caspases3/7, Bax/Bak, or ATG5 had no protective effect on FTY720-induced cell death in these immortalized MEFs (Fig 8A–C), which express endogenous I2PP2A/SET (Supporting Information Fig S11B). Consistent with these data, treatment with a pan-caspase inhibitor Z-VAD had no effect on A549 cell death in response to FTY720 (Fig 8D). Accordingly, ATG5−/− MEFs were more sensitive to taxol-induced apoptosis (80 nM and 24 h) as measured by increased caspase 3 activity compared to WT MEFs and used as an additional control to confirm their expected response to chemotherapy-induced apoptosis (Supporting Information Fig S11C). Overall, these data suggest that FTY720 induces cell death independently of caspase/Bax/Bak-mediated apoptosis or ATG5-mediated autophagy.
Because FTY720-mediated cell death was detected by elevated LDH, a measure of primary necrosis and plasma membrane breakdown, which occurs early during regulated necrosis or late during apoptosis (secondary necrosis), we determined the effects of necrostatin, an inhibitor of RIPK-1-mediated programmed necrosis (Degterev et al, 2008) (necroptosis), in this process. Pre-treatment with necrostatin significantly prevented (p < 0.05) cell death in response to FTY720 (Fig 8D). Accordingly, the genetic loss of RIPK1 (Ramnarain et al, 2008) almost completely abrogated cell death in response to FTY720 in RIPK1−/− MEFs compared to RIPK1+/+ MEFs (Fig 8E). These data were also consistent when endogenous RIPK1 was knocked down (about 80% compared to Scr-siRNA-transfected controls, measured by Western blotting; Fig 8F), FTY720-mediated cell death was blunted in A549 cells compared to controls (Fig 8G). Thus, these data suggest that FTY720-mediated cell death is regulated via induction of RIPK1-dependent necroptosis.
Because I2PP2A/SET-FTY720 binding activated PP2A, we explored the role of PP2A on RIPK1-induced necroptosis. Ectopic PP2Ac (catalytic domain) expression alone or in combination with FTY720 induced necroptosis, however, siRNA-mediated knockdown of RIPK1 prevented necroptosis in response to PP2Ac (Fig 9A). Induction of PP2A-dependent necroptosis by FTY720 was also detected in H157 (K-Ras mutant) and H827 (EGFR mutant) human lung cancer cells, in which inhibition of RIPK1 or PP2A using necrostastin or OA and knockdown of RIPK1 or PP2Ac prevented FTY720-mediated cell death compared to controls (Supporting Information Fig S12A–C). Interestingly, ectopic PP2Ac had no effect on FTY720-mediated cell death in RIPK1−/− MEFs compared to vector-transfected controls (Supporting Information Fig S13A). Interestingly, siRNA-mediated knockdown of RIPK3, a known inducer of necroptosis via MKLN activation (Sun et al, 2012), or Drp1, a downstream target of PGAM5, which is a recently identified necroptosis inducer (Wang et al, 2012), did not prevent FTY720-mediated A549 cell death (Supporting Information Fig S13B–D). In fact, knockdown of RIPK3 increased FTY720-mediated LDH release around twofold compared to controls (Supporting Information Fig S13D). Thus, these data indicate that PP2A activation plays an upstream role in selective RIPK1-dependent necroptosis by FTY720 in these cells.
RIPK1 is composed of three domains: kinase, intermediate and death domains. To explore which RIPK1 domains play a role in FTY720-induced necroptosis, death-domain-deletion mutant (DDD), kinase domain deletion mutant (DKD) and WT-RIPK1 were expressed in RIPK1−/− MEFs and their effects on FTY720-mediated necrosis were determined. Interestingly, WT-RIPK1 and DDD-RIPK1 restored FTY720-mediated necroptosis in RIPK1−/− MEFs, whereas DKD-RIPK1 expression had no effect on this process (Fig 9B). WT-, DDD- and DKD-RIPK1 expression was confirmed with Western blotting (Supporting Information Fig S14). Thus, these data suggest that FTY720-mediated necroptosis requires functional kinase domain of RIPK1 and that the death domain of RIPK1 is dispensible for this process. Overall, these data suggest that direct targeting of I2PP2A/SET by FTY720 induces PP2A/RIPK1-dependent necroptosis through its kinase domain, leading to cell death and subsequent tumour suppression.
In this study, we first characterized the details of interaction between endogenous ceramide and I2PP2A/SET, which is regulated by both structural characteristics and sub-cellular localization of I2PP2A/SET and/or ceramides with different fatty acid chain lengths, whose accumulation was altered in lung tumours. We then utilized these data to develop a novel strategy for lung cancer treatment via directly targeting I2PP2A/SET, which is highly expressed in these tumour tissues, by FTY720. Our novel data suggested that FTY720, but not P-FTY720, directly binds and targets I2PP2A/SET, mimicking ceramide/sphingosine, which activates tumour suppressor PP2A, subsequently suppressing lung tumour growth selectively via inducing RIPK1-mediated necroptosis (Fig 9C).
Molecular modelling/simulation studies suggested that the hydrophobic putative sphingolipid/ceramide-binding pocket of I2PP2A/SET is localized within the two anti-parallel beta sheet stabilized loops and an alpha helix, a common structural feature observed in CERT-ceramide binding (Kudo et al, 2008), which is possibly gated by interaction between K209 and Y122 residues. It should also be noted that although there are some structural similarities between binding sites of CERT and I2PP2A/SET to ceramide, there are also major differences. For example, ceramide binds to CERT with the two aliphatic chains packed against each other. The I2PP2A/SET model has the alkyl side chains splayed out in opposite directions. Moreover, the polar interactions of ceramide and CERT are nicely buried in the pocket, whereas in I2PP2A/SET ceramide interactions with K209 are on the surface and would have to compete with solvent, which might be less favourable. Therefore, details of precise binding site of I2PP2A/SET to ceramide need to be explored in future structural studies.
Our data also revealed that whereas the structural properties of I2PP2A/SET is important to determine its ceramide/sphingolipid binding, fatty acid chain length selectivity toward C18- versus C16-ceramide binding is mainly dependent upon nuclear versus ER localization of I2PP2A/SET. These data indicate that availability of C18- versus C16-ceramides for I2PP2A/SET binding in the nucleus versus ER membranes, respectively, is distinct in A549 cells. Overall, targeting I2PP2A/SET to different sub-cellular compartments might provide a unique molecular tool to probe the accumulation/availability of distinct ceramides in various cells.
Ceramide is known to play important functional roles in the nucleus, such as the regulation of SP3-HDAC1 suppressor function for the repression of hTERT (Wooten-Blanks et al, 2007). Interestingly, I2PP2A/SET is also involved in gene transcription and histone acetylation (Seo et al, 2001). However, how ceramides accumulate in nuclear membranes and whether ceramide–I2PP2A/SET interaction regulates only nuclear functions of PP2A and/or histone acetylation/deacetylation to suppress growth/proliferation remain unknown.
We also show here that FTY720 mimiks ceramide/sphingosine for I2PP2A/SET binding. Phosphorylation of FTY720 by SK-2 (Billich et al, 2003) is crucial for its anti-MS function via immune-suppression. However, whether anti-cancer functions of FTY720 (Pyne et al, 2011) are regulated via its phosphorylation is unclear. For example, in Jurkat cells, P-FTY720 analogue induces apoptosis (Don et al, 2007), whereas anti-cancer functions of FTY720, but not P-FTY720, have been shown in various different cancer models (Neviani et al, 2007; Roberts et al, 2010). Accordingly, our data elucidates that in lung cancer cells, phosphorylation of FTY720 by SK-2 might be dispensable for I2PP2A/SET targeting, which leads to necroptosis and lung tumour suppression. In contrast, loss of SK-2 prevented tumour suppression by FTY720 slightly (∼20–30%) in SK-2−/− compared to wt MEFs, indicating that P-FTY720 might play some roles in growth inhibition via I2PP2A/SET-PP2A-independent mechanisms in these cells. Alternatively, loss of SK-2 might affect the uptake/metabolism of FTY720, which would account for this slight decrease in tumour growth inhibition.
Mechanisms by which FTY720 mediates cell death are unclear. FTY720 was shown to induce apoptosis (Don et al, 2007) or caspase-independent cell death in acute lymphoblastic leukaemia cells (Wallington-Beddoe et al, 2011). Our novel data suggest that targeting I2PP2A/SET by FTY720 suppresses lung tumour growth via PP2A-dependent RIPK1 activation, leading to necroptosis (Bonapace et al, 2010; Cho et al, 2009; Christofferson & Yuan, 2010; Weinlich et al, 2011). Moreover, RIPK3/MKLN1 and PGAM5/Drp1 appear to be dispensable in this process; however, their roles in FTY720-mediated necroptosis and lung tumour suppression need to be further investigated. Importantly, our data revealed that the kinase domain, but not the death domain, of RIPK1 was required for FTY720-mediated necrosis, consistent with the role of the kinase domain of RIPK1 in the regulation of necroptosis (Cho et al, 2009; Hitomi et al, 2008; Holler et al, 2000), whereas the death domain of RIPK1 is associated with receptor-mediated cell death (Biton & Ashkenazi, 2011). However, whether the activation of PP2A directly regulates the kinase domain of RIPK1 for the induction of necroptosis in response to FTY720 remains unknown. Induction of necroptosis in tumours in response to FTY720 treatment was also monitored by the elevation of total LDH in serum, providing a unique serum marker to monitor tumour suppression in vivo. Moreover, it has been shown that FTY720 affects ceramide metabolism (Berdyshev et al, 2009; Lahiri et al, 2009). Consistent with recent studies (Berdyshev et al, 2009; Neviani et al, 2007), our data showed that FTY720 had no significant effect on total ceramide accumulation in tumours or serum of animals, indicating that FTY720-mediated tumour suppression might be independent of altered ceramide accumulation/metabolism.
In summary, by dissecting ceramide/sphingosine-I2PP2A/SET signalling, we identified that I2PP2A/SET is a novel drug target in human lung tumours and, more importantly, that it can be specifically targeted by the sphingosine analogue FTY720 leading to PP2A activation and RIPK1-dependent tumour necroptosis. Collectively, these data have important clinical implications for the development of novel and mechanism-based targeted therapeutics for the treatment of lung cancers.
MATERIALS AND METHODS
See Supporting Information for additional data (including full blots), and description of reagents, cell lines, culture conditions, Western blotting, IHC, ceramide/FTY720 measurements using LC/MS/MS, immunofluorescence/confocal microscopy, cloning and purification of recombinant human I2PP2A/SET, cell toxicity/survival assays, TEM, animal studies and statistical analysis.
Molecular modelling of I2PP2A/SET with ceramide or FTY720
Modelling and simulations were performed using MOE. Structural pbd files used were 2E50 for I2PP2A/SET (PMID 17360516) and 2E3P for CERT (PMID 18184806). Before analysis or simulations, proteins were protonated at pH 7.4 and structures energy minimized with heavy atoms constrained. Initial simulations focused on using ceramide as a probe for potential interaction sites, docked to the WT-I2PP2A/SET, or K209D-I2PP2A/SET homodimers using the entire surface as a target. Initial placement calculated 500 poses using triangle matching with London dG scoring, the top 250 poses were then refined using forcefield and ASE scoring. ProCAM analysis was performed using the SAPS ProCAM webserver (http://ci.vbi.vt.edu/cammer/saps.html; PMID: 14696387).
SPR binding assays
All SPR measurements were performed at 25°C as described (Stahelin and Cho, 2001). Briefly, after washing the sensor chip surface, 80 µl of vesicles containing either POPC:POPE (80:20) or POPC:POPE:x (75:20:5, where x = C18-ceramide, FTY720 or P-FTY720) were injected at 5 µl/min to give a response of 6200 resonance units (RU) where the POPC:POPE (80:20) surface serves as the control. Each lipid layer was stabilized by injecting 10 µl of 50 mM NaOH three times at 50 µl/min. SPR measurements were done at the flow rate of 5 µl/min where 80 µl of protein (I2PP2A/SET or p47phox-PX control) in 20 mM HEPES, pH 7.4, containing 0.16 M KCl was injected to monitor the association and dissociation phases of binding. To repeat binding measurements to the same lipid vesicles, the lipid surface was regenerated using five 10 µl injections of 50 mM NaOH at 50 µl/min. After sensorgrams were obtained in triplicate for each protein for each lipid condition, the ka and kd were determined from individual curves by separately fitting each curve with the BIAevaluation software (Biacore). From the ka and kd values, the equilibrium dissociation constant (Kd) was determined for each lipid surface using the equation Kd = kd/ka.
Detection of I2PP2A/SET–ceramide or -FTY720 binding
To measure the association between I2PP2A/SET or mutant I2PP2A/SET and endogenous ceramide (Saddoughi et al, 2011), I2PP2A/SET-wt or various mutant-I2PP2A/SET containing GFP tag were overexpressed in A549 cells. Next, over-expressed wt- and mutant-I2PP2A/SET were pulled down from cell extracts (equal amount of total protein was used for each sample) by immunoprecipitation using the µMACS™ GFP Tag protein isolation kit. The equal volume for each sample (after immunoprecipitation) was sent to Lipidomics Core Facility at MUSC (Bielawski et al, 2010) for endogenous ceramide measurement (normalized to inorganic phosphate, Pi) (Mukhopadhyay et al, 2009).
For FTY720 binding, I2PP2A/SET was purified from pTrc-I2PP2A/SET-HisA vector, and 1–2 µg were incubated with biotin or biotin-FTY720. The biotin or biotin-FTY720 was immunopreciptated with µMACS Streptavidin Kit (130-074-101), and the elution was run on SDS–PAGE and blotted for I2PP2A/SET. To evaluate FTY720 binding to the I2PP2A/SET mutants, I2PP2A/SET-WT-GFP and mutants were overexpressed in A549 lung cancer cells. The cells were lysed and incubated with biotin, or biotin-FTY720 and were immunoprecipitated with µMACS Streptavidin Kit in the absence/presence of FTY720, C18-ceramide, or P-FTY720. The eluted samples were run on SDS–PAGE and blotted for GFP.
PP2A activity assay
Protein lysate (100 µg) was used for PP2Ac immunoprecipitation with a phosphatase kit (Millipore), as described by the manufacturer.
SAS designed and performed experiments, analysed and interpreted data, performed statistical analysis, made the figures, and wrote the manuscript; SG, KEW, AM, JO, RJT, SPS and CES performed experiments; YKP performed the structural analysis and docking simulations; JB measured ceramides and FTY720 by LC/MS/MS; ZMS designed and synthesized ceramide and FTY720 analogues. EGM performed statistical analysis of data, AL helped IHC staining/scoring, AAH generated/provided RIPK1-related molecular tools/models, RMDP and DF performed experiments for expression of recombinant I2PP2A/SET, DP and RVS helped design experiments, and BO conceived/designed experiments, analysed data, and wrote the manuscript.
We thank Dr. Jennifer G. Schnellmann (Medical University of South Carolina, MUSC) for editorial review. We thank Drs. L.M. Obeid (MUSC), D. Green (St. Jude Children's Research Hospital), R.A Flavell (Yale), and N. Mizushima (Tokyo Medical and Dental University) for providing us with the SK-1−/− and SK-2−/−, Bax/Bak−/− DKO, caspase 3−/−/7−/− DKO, and ATG5−/− MEFs, respectively. We also thank Dr. Rosalie Sears (OSHSU) for providing c-Myc plasmids to our laboratory. We would like to thank David Sentelle, and Drs. Mayuri Rajapurkar, and Suriyan Ponnusamy for their technical assistance, services and/or discussions. TEM slides were kindly analysed by Dr. D. Hazen-Martin (MUSC). This work was supported by research grants obtained from the National Institutes of Health (CA088932, DE016572 and CA097165 to BO; AI081077 to RVS; NS062080; and F30ES019464 to SAS). KEW is supported by an AHA pre-doctoral fellowship (11PRE7640028) and a NIH CBBI training fellowship (T32GM075762). DP is a Scholar of The Leukemia and Lymphoma Society and is supported by R01 CA163800 and CA095512, and by the US Army CML Research Program W81XWH-07-1-0270. JJ Oaks is a student of the OSU Integrated Biomedical Graduate Program. In addition, SAS was supported by scholarships provided by Wachovia and Abney Foundations. SG was sponsored by a fellowship from The Scientific and Technological Research Council of Turkey through International Postdoctoral Research Scholarship Program, at the Department of Genetics and Bioengineering, Faculty of Engineering, Fatih University, Istanbul, Turkey. The core facilities utilized for animal studies, tumour bank, flow cytometry and lipidomics were constructed using support from NIH (C06 RR015455).
Supporting Information can be found at EMBO Molecular Medicine online.
The authors declare that they have no conflict of interest.